Scaling Home-Based Decongestion in Heart Failure With FUROSCIX® (Furosemide Injection)

Description

Heart failure remains one of the leading causes of costly hospital admissions, with persistent congestion driving emergency visits, readmissions and significant symptom burden – even as advances in therapy continue. Traditional care models often intervene too late, relying on inpatient intravenous diuresis when oral medications fail, and leaving a critical gap for patients with chronic kidney disease or those at risk of diuretic resistance. The upcoming Centers for Medicare & Medicaid Services (CMS) Ambulatory Specialty Model (ASM) for HF further raises the stakes, shifting accountability and financial risk to the ambulatory setting and making avoidable hospitalizations and emergency department visits a direct threat to program performance. Drawing on real-world experience from Cone Health and Emory Health System, an upcoming webinar and a new roadmap will provide a scalable framework for cardiovascular leaders seeking to implement home-based decongestion with FUROSCIX® (furosemide injection) safely, efficiently and in alignment with CMS ASM and value-based care.

Speakers

Daniel Bensimhon, MD
Advanced Heart Failure Program Director, Cone Health

Amy Clegg, MSN, NP-C, CHFN
Chief APP AHF/HV Specialty Services, Cone Health

Nicole Dellise, DNP, APRN, FNP-BC, NEA-BC, CHFN, CCK, FACC
Vice President, Care Transformation, MedAxiom